Celsion Corporation (NASDAQ:CLSN) investors have a smile on their faces Thursday morning, after the tiny drug maker won FDA clearance for OVATION II Study, …
The Good: Oppenheimer Sees Celsion Corporation Shares Soaring About 180% Over 12 Months It can be tricky putting a price tag on a …
Oppenheimer’s Hartaj Singh sees 227% upside potential for CLSN.
Today, shareholders of Celsion Corporation (NASDAQ:CLSN) woke up to a nice 5% pop in the value of their shares, after the drug maker announced …
Shares of Celsion Corporation (NASDAQ:CLSN) dived nearly 20% in morning trade Friday, after the drug maker’s stock offering priced at a deep discount. The …
Celsion Corporation (NASDAQ:CLSN) announced publication of the manuscript, “Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable …
Celsion Corporation (NASDAQ:CLSN) announced that it will host a Research and Development (R&D) Day for investors and analysts on Thursday, October 12, 2017. …
Celsion Corporation (NASDAQ:CLSN) shareholders are stoked in anticipation for tomorrow’s R&D Day conference set in New York City, with shares experiencing a just …
Celsion strikes iron while its hot to raise $15.6 million; Catabasis slows rate of DMD decline in OLE trial.
Take a gander at bullish Q2 plays in biotech from one of the richest men in the business.